Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 55.24 (+1.79), UTHR: 130.22 (+2.40)
Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension
Thomson Reuters ONE - Mon Dec 22, 5:01PM CST
Actelion Pharmaceuticals Ltd / Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.03), PFNX: 7.33 (-0.05), INO: 9.11 (-0.09), CMRX: 36.80 (+0.70), RPTP: 9.34 (+0.56), IBIO: 0.68 (-0.04), ANAC: 30.58 (+0.16), PFE: 31.42 (-0.03), GNCA: 7.42 (-0.11), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), NVS: 93.91 (+0.66)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.46 (unch), GILD: 91.29 (+1.84), UTHR: 130.22 (+2.40), GSK: 42.85 (+0.11), ARNA: 3.57 (-0.01)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 340.89 (+5.13), UTHR: 130.22 (+2.40)
Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension
Thomson Reuters ONE - Mon Dec 01, 5:00PM CST
Actelion Pharmaceuticals Ltd / Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST
TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), ROG: 80.02 (+1.50), CEMP: 20.66 (+0.78)
Tetraphase mulling selling itself
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 7:40AM CST
JNJ: 104.59 (+0.31), TTPH: 38.86 (+0.53), MRK: 57.46 (+0.25)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 1.50 (unch), SGEN: 31.10 (-0.14)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 1.50 (unch), SGEN: 31.10 (-0.14)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 99.23 (+1.23), HALO: 9.34 (+0.31), LGND: 51.79 (+1.22)
Actelion delivers strong nine months results
Thomson Reuters ONE - Tue Oct 21, 12:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion delivers strong nine months results . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
ANAC: 30.58 (+0.16), FRX: 99.00 (-0.77), OMER: 22.09 (+0.48)
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
TGTX: 16.03 (+0.33), LGND: 51.79 (+1.22), AMGN: 160.67 (+3.15)
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.
GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25)
Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.
GILD: 91.29 (+1.84), ILMN: 186.22 (+2.72)
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), TROV: 4.37 (+0.07)
NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose almost 9% on the day.
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), NLNK: 39.08 (+1.36)
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.
CBM: 21.62 (+0.37), ACHN: 13.06 (+1.22), ILMN: 186.22 (+2.72)
Epizyme (EPZM) Crumbles: Stock Falls by 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:33AM CDT
Epizyme has been witnessing a flat movement in its earnings estimate front and its share price has been declining for past 24 hours
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), EPZM: 17.71 (+0.01)